Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>e-Therapeutics offers public market investors a unique opportunity to gain exposure to a proprietary, cutting-edge in silico drug discovery platform that has already attracted significant investment and has been fully operational since 2014. This second-generation platform has generated new chemical entities (NCEs) in several different disease areas and, under a new CEO, is on the cusp of commercial validation. The priority for the company is securing deals to provide external validation of this approach. e-Therapeutics&#8217; strength is its discovery capability, particularly in complex disease; it also has six internal discovery projects with the prospect of more to come. The CEO&#8217;s business review will determine the focus of internal investment and business development activities. </p>

e-Therapeutics offers public market investors a unique opportunity to gain exposure to a proprietary, cutting-edge in silico drug discovery platform that has already attracted significant investment and has been fully operational since 2014. This second-generation platform has generated new chemical entities (NCEs) in several different disease areas and, under a new CEO, is on the cusp of commercial validation. The priority for the company is securing deals to provide external validation of this approach. e-Therapeutics&#8217; strength is its discovery capability, particularly in complex disease; it also has six internal discovery projects with the prospect of more to come. The CEO&#8217;s business review will determine the focus of internal investment and business development activities. 

<p>e-Therapeutics (ETX) has appointed a new CEO, Dr Raymond Barlow, who will join the company by 1 May 2017. He brings significant R&amp;D and business development experience, which will be invaluable in driving ETX to the next stage of its evolution. Following its 2016 strategic review, ETX&rsquo;s near- to mid-term focus is on deriving value from its proprietary network pharmacology discovery platform. Potential deals from late 2017 would provide external validation for the platform and differentiated discovery approach, and generate revenues. Portfolio rationalisation secures ETX&rsquo;s funding runway into early 2019; deal flow would extend this. Preclinical data on the five core discovery assets should stimulate interest from potential partners/collaborators. Deals and data are the next key catalysts.</p>

e-Therapeutics (ETX) has appointed a new CEO, Dr Raymond Barlow, who will join the company by 1 May 2017. He brings significant R&amp;D and business development experience, which will be invaluable in driving ETX to the next stage of its evolution. Following its 2016 strategic review, ETX&rsquo;s near- to mid-term focus is on deriving value from its proprietary network pharmacology discovery platform. Potential deals from late 2017 would provide external validation for the platform and differentiated discovery approach, and generate revenues. Portfolio rationalisation secures ETX&rsquo;s funding runway into early 2019; deal flow would extend this. Preclinical data on the five core discovery assets should stimulate interest from potential partners/collaborators. Deals and data are the next key catalysts.

Embarking on the next phase: Deals and data

United Kingdom

e-Therapeutics PLC is a systems biology drug discovery company.  The Company uses computers to predict the effects of intervention to proteins in a cell.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

e-Therapeutics PLC (ETX LN)

Right place, right time

e-Therapeutics offers public market investors a unique opportunity to gain exposure to a proprietary, cutting-edge in silico drug discovery...

Edison Investment Research

Embarking on the next phase: Deals and data

e-Therapeutics (ETX) has appointed a new CEO, Dr Raymond Barlow, who will join the company by 1 May 2017. He brings significant R&D and...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)